| scholarly article | Q13442814 |
| P50 | author | Axel Schambach | Q42229187 |
| P2093 | author name string | Manuel Grez | |
| Christopher Baum | |||
| Hana Kunkel | |||
| Joachim Schwäble | |||
| Linping Chen-Wichmann | |||
| Christian Brendel | |||
| Kerstin B Kaufmann | |||
| Julia D Suerth | |||
| Shweta Pahujani | |||
| Uta Mueller-Kuller | |||
| P2860 | cites work | Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia | Q24618997 |
| Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences | Q24798872 | ||
| Gene therapy for primary immunodeficiencies | Q26864856 | ||
| Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production | Q28114945 | ||
| Residual NADPH oxidase and survival in chronic granulomatous disease | Q28301969 | ||
| Transcription start regions in the human genome are favored targets for MLV integration | Q29618456 | ||
| Clinical aspects of chronic granulomatous disease | Q31804597 | ||
| Progress in gene therapy for chronic granulomatous disease | Q33542352 | ||
| Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis | Q33713961 | ||
| Resistance of mature T cells to oncogene transformation | Q46357501 | ||
| Occurrence of cytochrome b558 in B-cell lineage of human lymphocytes | Q68446886 | ||
| Kinetic microplate assay for superoxide production by neutrophils and other phagocytic cells | Q68484796 | ||
| Monoclonal antibody 7D5 raised to cytochrome b558 of human neutrophils: immunocytochemical detection of the antigen in peripheral phagocytes of normal subjects, patients with chronic granulomatous disease, and their carrier mothers | Q68949088 | ||
| Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells | Q81353679 | ||
| Stable transgene expression in primitive human CD34+ hematopoietic stem/progenitor cells, using the Sleeping Beauty transposon system | Q33888773 | ||
| A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells | Q34074917 | ||
| Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease | Q34094502 | ||
| Lineage- and stage-restricted lentiviral vectors for the gene therapy of chronic granulomatous disease | Q34182786 | ||
| Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells | Q34473359 | ||
| Gene therapy of chronic granulomatous disease: the engraftment dilemma | Q34473374 | ||
| Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. | Q34508425 | ||
| Chronic granulomatous disease: lessons from a rare disorder | Q34644316 | ||
| Murine hematopoietic stem cells change their surface phenotype during ex vivo expansion | Q35847607 | ||
| Human T-cell leukemia virus type 1 integration target sites in the human genome: comparison with those of other retroviruses | Q35857184 | ||
| Gene transfer into mammalian cells by a Rous sarcoma virus-based retroviral vector with the host range of the amphotropic murine leukemia virus | Q35861853 | ||
| Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations. | Q35913748 | ||
| Alpharetroviral self-inactivating vectors: long-term transgene expression in murine hematopoietic cells and low genotoxicity. | Q35939492 | ||
| Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts | Q35944232 | ||
| Lentiviral vector induced insertional haploinsufficiency of Ebf1 causes murine leukemia | Q36014047 | ||
| The β-globin locus control region in combination with the EF1α short promoter allows enhanced lentiviral vector-mediated erythroid gene expression with conserved multilineage activity | Q36054608 | ||
| Silencing and variegation of gammaretrovirus and lentivirus vectors | Q36301560 | ||
| Gene targeting of X chromosome-linked chronic granulomatous disease locus in a human myeloid leukemia cell line and rescue by expression of recombinant gp91phox | Q36616258 | ||
| Modern management of chronic granulomatous disease | Q37064440 | ||
| Transduction of terminally differentiated neurons by avian sarcoma virus | Q37423151 | ||
| Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications | Q37553909 | ||
| Genome-wide analyses of avian sarcoma virus integration sites | Q37583468 | ||
| Physiological regulation of transgene expression by a lentiviral vector containing the A2UCOE linked to a myeloid promoter. | Q39445622 | ||
| Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy | Q39488638 | ||
| Genetic correction of X-linked chronic granulomatous disease with novel foamy virus vectors | Q39572291 | ||
| A ubiquitous chromatin opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral vectors | Q39686980 | ||
| Self-inactivating alpharetroviral vectors with a split-packaging design | Q39712155 | ||
| Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells. | Q39941137 | ||
| Physiological promoters reduce the genotoxic risk of integrating gene vectors | Q40003414 | ||
| Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. | Q40027548 | ||
| Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression | Q40365103 | ||
| Variegation of retroviral vector gene expression in myeloid cells | Q40900199 | ||
| Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy | Q45865095 | ||
| Site-specific integration and tailoring of cassette design for sustainable gene transfer. | Q45872654 | ||
| P433 | issue | 3 | |
| P921 | main subject | gene therapy | Q213901 |
| P304 | page(s) | 648-661 | |
| P577 | publication date | 2012-12-04 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing | |
| P478 | volume | 21 |
| Q38772068 | Alpharetroviral self-inactivating vectors produced by a superinfection-resistant stable packaging cell line allow genetic modification of primary human T lymphocytes |
| Q38285765 | Alpharetroviral vectors: from a cancer-causing agent to a useful tool for human gene therapy |
| Q36358611 | An assessment of the effects of ectopic gp91phox expression in XCGD iPSC-derived neutrophils. |
| Q40414488 | Application of Droplet Digital PCR for Estimating Vector Copy Number States in Stem Cell Gene Therapy |
| Q40272131 | Detailed comparison of retroviral vectors and promoter configurations for stable and high transgene expression in human induced pluripotent stem cells |
| Q37132611 | Development of gene therapy for blood disorders: an update |
| Q40156250 | Engineering Next-Generation BET-Independent MLV Vectors for Safer Gene Therapy |
| Q92137870 | Enhancing Lentiviral and Alpharetroviral Transduction of Human Hematopoietic Stem Cells for Clinical Application |
| Q33819841 | Gene and cell therapy for children--new medicines, new challenges? |
| Q27007012 | Gene therapy on the move |
| Q35184193 | Generation of X-CGD cells for vector evaluation from healthy donor CD34(+) HSCs by shRNA-mediated knock down of gp91(phox). |
| Q33891707 | Genome-wide analysis of alpharetroviral integration in human hematopoietic stem/progenitor cells. |
| Q89965508 | High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia |
| Q64093236 | Lentiviral Vectors for the Treatment and Prevention of Cystic Fibrosis Lung Disease |
| Q39094431 | Retroviral Vectors for Cancer Gene Therapy |
| Q36176014 | Towards a Safer, More Randomized Lentiviral Vector Integration Profile Exploring Artificial LEDGF Chimeras |
Search more.